Omeprazole And Sodium Bicarbonate
NDC Package 68682-991-30

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Omeprazole And Sodium Bicarbonate is contraindicated in patients with known hypersensitivity to any components of the formulation. Marketed by Oceanside Pharmaceuticals, this product is identified by NDC 68682-991 and is authorized under FDA application NDA021636.

Identification & Billing

NDC Package Code
68682-991-30
Package Description
30 PACKET in 1 CARTON / 1 POWDER, FOR SUSPENSION in 1 PACKET
Product Code
68682-991
11-Digit Billing Format
68682099130
RxNorm Crosswalk
  • RxCUI: 616539 - omeprazole 20 MG / sodium bicarbonate 1100 MG Oral Capsule
  • RxCUI: 616539 - Omeprazole 20 MG / NaHCO3 1100 MG Oral Capsule
  • RxCUI: 616541 - omeprazole 40 MG / sodium bicarbonate 1100 MG Oral Capsule
  • RxCUI: 616541 - Omeprazole 40 MG / NaHCO3 1100 MG Oral Capsule
  • RxCUI: 753557 - omeprazole 40 MG / sodium bicarbonate 1680 MG Powder for Oral Suspension

Clinical Specifications

Proprietary Name
Omeprazole And Sodium Bicarbonate
Dosage Form
-
Usage Information
Omeprazole and Sodium Bicarbonate is contraindicated in patients with known hypersensitivity to any components of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, and urticaria. [See Adverse Reactions (6)].

Regulatory & Marketing

Labeler Name
Oceanside Pharmaceuticals
FDA Application #
NDA021636
Marketing Category
NDA AUTHORIZED GENERIC - A product marketed as a "generic" drug under an approved New Drug Application (NDA), rather than an Abbreviated New Drug Application (ANDA),.
Start Marketing Date
06-15-2004
End Marketing Date
04-30-2026
Listing Expiration
04-30-2026
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68682-991-30 identifies a specific commercial package of 30 packet in 1 carton / 1 powder, for suspension in 1 packet of Omeprazole And Sodium Bicarbonate, labeled by Oceanside Pharmaceuticals. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Oceanside Pharmaceuticals on June 15, 2004. The current certification is valid through April 30, 2026.

How is this Oceanside Pharmaceuticals product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68682099130. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
68682-991-30
11-Digit CMS (5-4-2)
68682-0991-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.